Drs Park and Kasi discuss the rise of neoadjuvant immunotherapy in CRC management, framing how this shift fits into the context of larger paradigm changes.
Podcasts
Recent Episodes
All series
All Podcasts
Advertisement
Nataliya Uboha, MD, PhD, discusses zanidatamab-based regimens, their recent approval, and the HERIZON-GEA-01 trial in gastric cancer.
Drs Florez and Riess discuss the distinction between HER2 overexpression and HER2 mutations in non–small cell lung cancer.
Davide Melisi, MD, PhD, discusses INCB161734 and the DAWN-303 trial evaluating the agent in KRAS G12D–mutated metastatic pancreatic ductal adenocarcinoma.
Raji Shameem, MD, and Shubham Pant, MD, MBBS, discuss the evolving pancreatic cancer treatment paradigm and novel treatments.
Drs Park and Brody highlight the rapidly evolving treatment landscape for B-cell lymphomas, noting advances across frontline and relapsed settings.
Drs Nunnery and Kurian discuss the role of artificial intelligence in oncology, beginning with foundational concepts.
Drs Armstrong and Tawagi deliver a comprehensive, board-focused review of metastatic NSCLC diagnosis and management for 2026.
Advertisement
Drs Camidge and Petrillo discuss Dr Petrillo's evolution from a science-curious student to a leader in palliative care research.
Drs Nunnery and Bonaminio discuss breast cancer screening amid recent conflicting guidelines, beginning with an overview of the breast radiologist's role.
Two Onc Docs gives a board-focused review of early-stage and locally advanced NSCLC, reflecting recent shifts in staging and perioperative therapy.
Dr Wong discusses the significance of the FDA’s accelerated approval of vusolimogene oderparepvec-wtpg plus nivolumab in unresectable advanced cutaneous melanoma.
Eric D. Whitman, MD, and Francis Paul Worden, MD, discuss the integration of immunotherapy into the CSCC treatment paradigm.
Sagar Lonial, MD, FACP, FASCO, shares the significance of the FDA approval of iberdomide/daratumumab/dexamethasone in replased/refractory multiple myeloma.
Drs Park and Brody discuss the evolving frontline and relapsed treatment landscape in Hodgkin lymphoma.
Dr Valerin discusses the role of liposomal irinotecan in pancreatic cancer management and factors influencing the decision to use this agent in practice.
Drs Nunnery and Teplinsky discussed how to manage the adverse effects associated with endocrine therapy in hormone receptor–positive breast cancer.
Dr Brufsky discusses the FDA approval of gedatolisib plus fulvestrant ± palbociclib for hormone receptor–positive, PIK3CA wild-type advanced breast cancer.
Jonathan Trent, MD, PhD, discusses the clinically available TKIs for GIST and the potential benefits of liquid TKI formulations for this disease.
Drs Nunnery and Sunshine discuss how breast cancer therapies affect the eye, beginning with a primer on ocular anatomy.
Douglas W. Sborov, MD, MS, discussed the FDA approval of isatuximab for subcutaneous injection in multiple myeloma indications.
Dr Peters discussed the rationale for pairing antiangiogenic activity with checkpoint inhibition upfront in NSCLC, rather than sequencing them.
Drs Park and Liu discuss precision oncology, bispecific antibodies, and next-generation targeted therapies in NSCLC.
Biomarker-Driven Shifts Signal the Next Generation of mCRC Therapies: With Tanios S. Bekaii-Saab, MD
Dr Bekaii-Saab discusses the current state of the metastatic colorectal cancer treatment landscape and potential future research directions.
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
Etentamig Improves Response and PFS vs Standard Therapies in Triple-Class Exposed Relapsed/Refractory Myeloma
3
Dr Voorhees on Eligibility Criteria for the CERVINO Trial in Multiple Myeloma
4
FDA Approves Lirafugratinib for Pretreated, Locally Advanced or Metastatic Cholangiocarcinoma
5